A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Trial Profile

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2018

At a glance

  • Drugs LN 145 (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 24 Jan 2018 Preliminary results from the study presented in an Iovance Biotherapeutics media release.
    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, the company has amended the protocol so that newly enrolled patients can be treated using TIL produced from the Gen 2 manufacturing process.
    • 13 Dec 2017 According to an Iovance Biotherapeutics media release, the study is enrolling patients in the Unites States and is expected to start enrollment of patients in Europe in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top